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Abstract 
The imprinted 11p15 region is organized in two domains, each of them 
under  the  control  of  its  own  imprinting  control  region  (ICR1  for  the 
IGF2/H19 domain and ICR2 for the KCNQ1OT1/CDKN1C domain).
Disruption of 11p15 imprinting  results in two fetal growth disorders with 
opposite phenotypes:  the Beckwith-Wiedemann (BWS) and the Silver-
Russell (SRS) syndromes. Various 11p15 genetic and epigenetic defects 
have been demonstrated in BWS and SRS. Among them, isolated DNA 
methylation  defects  (ICR1  gain  of  methylation  or  ICR2  loss  of 
methylation in BWS and ICR1 loss of methylation in SRS) account for 
approximately 60% of patients.
To investigate whether cryptic Copy Number Variations (CNVs) involving 
only part of one of the two imprinted domains account for 11p15 isolated 
DNA  methylation  defects,  we  designed  a  Single  Nucleotide 
Polymorphism  array  covering  the  whole  11p15  imprinted  region  and 
genotyped one hundred eighty five SRS or BWS cases with loss or gain 
of DNA methylation at either ICR1 or ICR2.
We describe herein novel small gain and loss CNVs in six BWS or SRS 
patients,  including  maternally-inherited  cis-duplications  involving  only 
part of one of the domains in SRS and BWS patients. We also show that 
i) ICR2 deletions do not account for BWS with ICR2 loss of methylation 
and  ii)  uniparental  isodisomy involving  only  one  of  the  two  imprinted 
domains is not a mechanism for SRS or BWS. 
Those novel defects led new light in the regulation of 11p15 genomic 
imprinting.
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Introduction
Human chromosome 11p15.5 contains a cluster of imprinted genes that 
play  a  crucial  role  in  the  control  of  fetal  growth  1-4.  This  cluster  is 
organized in two neighboring imprinted domains, the  IGF2/H19 and the 
KCNQ1OT1/CDKN1C domains,  each of  them under  the  control  of  its 
own  imprinting  control  region,  ICR1  and  ICR2  respectively.  Aberrant 
genomic  imprinting  of  the  11p15  region  has  a  pivotal  role  in  both 
Beckwith-Wiedemann  (BWS;  MIM  130650)  and  Silver-Russell  (SRS; 
MIM 180860) syndromes. BWS is characterized by pre-and/or postnatal 
overgrowth  and  other  features  including  hemihyperplasia  and  an 
increased risk of childhood tumors. SRS is characterized by severe pre- 
and  postnatal  growth  retardation,  dysmorphic  facial  features,  feeding 
difficulties and body asymmetry. 
Various 11p15 molecular  aberrations  including genetic  and epigenetic 
abnormalities  have  been  demonstrated  in  BWS and  SRS  5-8.  Among 
genetic defects, paternal isodisomy of the 11p15 region involving the two 
imprinted domains is a classical cause of BWS and accounts for 20-25% 
of BWS cases 5, 9, 10, whereas maternal isodisomy has been reported in 
only one SRS case 11. Approximately ten unbalanced translocations (gain 
CNV) involving both imprinted domains have also been described. When 
familial,  these  translocations  result  in  a  fetal  growth  retardation 
phenotype  when  maternally-inherited  and  an  overgrowth  phenotype 
when  paternally-inherited,  as  reviewed  in  12. Nevertheless,  epigenetic 
defects (i.e gain or loss of DNA methylation at either ICR1 or ICR2) are 
very frequent and account for approximately  60-70% of BWS and SRS 
patients.  DNA methylation defects involving ICR2 (loss of methylation) 
result  in  BWS  (60%  of  cases)  whereas  DNA  methylation  defects 
involving ICR1 result in both BWS (gain of methylation, 10% of cases) 
and  SRS  (loss  of  methylation,  50-60%  of  cases)  5-7,  13.  For  a  small 
percentage of those patients, the DNA methylation defect is secondary. 
Mutations/deletions  in ICR1 cis-regulatory elements account for 20% of 
BWS patients with ICR1 gain of methylation  14-18,  whereas deletions in 
ICR2  cis-regulatory elements in BWS patients have been exceptionally 
reported 19, 20. On the other hand, in a subset of BWS patients (25%) with 
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ICR2 loss  of  methylation  and  SRS patients  (10%)  with  ICR1  loss  of 
methylation,  the loss of  methylation  involves imprinted loci  other  than 
11p15 suggesting the dysregulation of an unidentified trans-acting factor 
controlling  the  establishment  and/or  the  maintenance  of  genomic 
imprinting  at  several  loci  21-26.  Altogether,  these  secondary  DNA 
methylation defects (deletion of a  cis-regulatory element or involvement 
of a trans-acting regulatory factor) account for a small group of BWS and 
SRS cases and the mechanism of the DNA methylation defect remains 
unexplained in most cases. 
Conventional  diagnostic  tools  used  in  11p15  fetal  growth  disorders 
present  either  a  low resolution  level  (>  500 kb),  (i.e caryotype,  FISH 
analysis) or high resolution level (< 5 kb), (sequencing, DNA methylation 
analysis,  Multiplex  ligation-dependent  probe  amplification, long-range 
PCR) and they might fail to recognize intermediate CNVs, ranging from 5 
to  500  kb.  Assessment  of  small  segmental  CNVs  has  not  been 
systematically addressed in SRS and BWS patients with isolated DNA 
methylation  defects.  To  investigate  whether  cryptic  CNVs account  for 
11p15  isolated  DNA  methylation  defects,  we  designed  a  customized 
Single Nucleotide Polymorphism (SNP) array (1536 SNPs) covering the 
whole  11p15  imprinted  region.  We  genotyped  a  large  series  of  one 
hundred  eighty  five  SRS  and  BWS cases  with  loss  or  gain  of  DNA 
methylation at either ICR1 or ICR2. We describe herein novel gain and 
loss CNVs in both BWS and SRS patients. 
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Subjects and Methods
Subjects 
This study was conducted in compliance with institutional guidelines for 
research studies in human genetics (approval no. 253/07, Alfred Hospital 
Ethics  Committee and  agreement  numbers  681  and  682,  Assistance 
Publique-Hôpitaux de Paris)  and informed consent  was obtained from 
participating  individuals  and/or  their  parents.  The  study  population 
consisted of 50 ethnically matched control subjects and 185 patients with 
growth  disorders  caused  by  a  DNA methylation  defect  of  the  11p15 
domain.  A  subset  of  BWS  and  SRS  patients  with  abnormal  DNA 
methylation at ICR1 was analyzed in a previous study  18. Patients with 
cytogenetic abnormalities, 11p15 parental isodisomy or  CDKN1C gene 
mutation  and  patients  with  a  multilocus imprinting  disorder  21;  22 were 
excluded from the study. Biparental inheritance of the 11p15 region was 
shown by Southern-blot and/or microsatellite analysis. 
One hundred and thirteen patients were diagnosed with BWS. Seventy-
eight of them displayed a loss of methylation at ICR2. Thirty-five BWS 
patients displayed a gain of methylation at ICR1. Nine BWS cases (six 
with ICR2 loss of methylation and three with ICR1 gain of methylation) 
were fetal cases (medically terminated pregnancies in 50% of cases and 
spontaneous abortion in 50% of cases). Five BWS cases were familial 
forms  (one  with  ICR2  loss  of  methylation  and  four  cases  from  two 
families with ICR1 gain of methylation). 
Seventy-two  patients  were  SRS  patients  who  displayed  loss  of 
methylation at ICR1.  
Parental DNA was available for 110 (59%) BWS or SRS patients. In 93 
cases, DNA was available from both parents. Non-paternity was found in 
three BWS cases with ICR2 loss of DNA methylation and only maternal 
DNA was considered in those cases.
The  clinical  and  molecular  data  of  BWS  and  SRS  patients  are 
summarized in tables 1 and 2.
Methods
Selection of SNP probes and Oligo Pool Assay design
An Oligo Pool  Assay (OPA) of 1536 SNPs covering the whole 11p15 
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region (location on chromosome 11: position 1,970,084-2,869,522, NCBI 
36/hg18  assembly)  and  including  the  two  imprinted  domains  was 
designed. To allow a high success rate of genotyping, only SNPs with an 
Illumina SNP_score >0.6 were selected among the 6214 polymorphisms 
present in dbSNP130 and located in the region of interest. SNPs already 
genotyped in the HapMap CEU population (our disease panel consists 
mostly  of  European  individuals)  were  preferentially chosen.  They 
represent 648 SNPs out of the 1536 final dataset. We selected SNPs 
dispersed homogenously along the domain with a final density of 1 to 3 
probes  per  kilobase.  Moreover,  regions  corresponding  to  the  two 
imprinting control regions (ICR1 and ICR2) were enriched with a density 
of one probe every 300 bp. The customized OPA was used to genotype 
patients, their parents and some of the family members as well as control 
samples on the iScan System (http://www.illumina.com) according to the 
manufacturer’s protocol.
Preparation of SNP data
We generated a total of ~ 735 000 genotypes in 473 samples. Genotypes 
were  analyzed  using  the  Illumina  GenomeStudio  software 
(http://www.illumina.com). After reclustering, 8 samples with a call rate 
<95%  and  340  probes  with  excessive  noise  or  aberrant  clustering 
patterns (based on the  GenTrain Score and manual  inspection)  were 
permanently excluded from further analysis. Following a series of quality 
control steps, an initial design using 1536 SNPs and 473 individuals was 
reduced to a final dataset of 1196 SNPs and 465 samples (including the 
185 patients and 50 control subjects). 
CNVs detection by Illumina and QuantiSNP v2.3 softwares
Analysis of CNVs was done based on log R ratio and B allele frequency 
values  issued  from  the  Illumina  GenomeStudio  and  Beadstudio  v3.1 
softwares.  Firstly,  we  used  the  cnvPartition  v2.4.4  plug-in 
(http://www.illumina.com)  implemented  in  the  Illumina  GenomeStudio 
software to identify CNVs. Given the density of probes in the OPA (one to 
three per kb), CNVs as small as 1 kb could be potentially detected. We 
performed a non-stringent analysis considering 3 consecutive probes, a 
minimum  size  of  1,000  bp  and  a  threshold  of  35  according  to  the 
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program.  Because  the  cnvPartition  algorithm  uses  an  undocumented 
method of CNV detection, we also used the QuantiSNP v2.3 software 
developed by Colella  et  al.  27.  QuantiSNP based on Objective  Bayes 
Hidden-Markov  Model  treats  independently  log  R  ratio  and  B  allele 
frequency and has been shown to outperform other softwares  28.  The 
analysis  was performed using default parameters  27 and  a score (Log 
Bayes Factor) was assigned to each identified CNV; only CNVs with a 
stringent threshold score (Log Bayes Factor >30) have been considered. 
Secondly,  to identify  runs of homozygosity,  we used the Homozygosity 
Detector  plug-in  (http://www.illumina.com)  implemented  in  the  Illumina 
BeadStudio v3.1 software as well as the QuantiSNP v2.3 software. The 
analysis  was  performed  using  the  default  parameters  of  the 
Homozygosity  Detector program.  All  regions  with  more  than  50 
homozygous and a cutoff significance χ2>23.5 were marked as runs of 
homozygosity. For the analysis using the QuantiSNP v2.3 software, only 
runs of homozygosity with a Log Bayes Factor > 30 were considered.
Validation of identified CNVs by quantitative real-time PCR analysis 
and CGH array
Quantitative real-time PCR: Validation of CNVs identified from the SNP 
array was performed by quantitative real time PCR. We designed at least 
5 primer sets located within and outside the region of interest to confirm 
the CNVs and map their limits. Quantitative real time PCR was carried 
out by using a 7500 fast real time PCR system (ABI systems) and Fast 
SYBR green mix (Roche). Data expressed as the relative quantification 
were normalized to a region located in the neurogenin 1 gene in which no 
genetic  variation  has  been  described.  Two  normal  individuals  were 
included. All primers used in this study are listed in Supplementary table 
1.
CGH array: Validation of some CNVs identified from the SNP array was 
performed  using the  244K Agilent - Human CpG Island Microarray Kit 
(patient  S72P)  or  the  4x180K  Agilent-Human  Genome Microarray  Kit 
(patient H47P) (Agilent Technologies, Santa Clara, CA, USA).
Bisulfite sequencing
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Bisulfite sequencing was performed as previously described  18.  Primers 
used in this study are listed in Supplementary table 1.
Karyotyping and FISH characterisation
Chromosomes were prepared from peripheral blood lymphocyte cultures 
following standard procedures. Fluorescence in situ hybridization (FISH) 
using  chromosome 11 specific subtelomeric probes  (patient H47P)  was 
performed  according  to  the  manufacturer’s  specifications  (Abbott 
molecular/Vysis,  USA). The BAC probes used in other FISH analyses 
include RP11-295K3 and RP3-416J11 (patient S72P) and CTD-2242D18 
(patient L65P). 
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 Results
Several parameters were used to assess the likelihood of pathogenicity 
of a CNV in this study:  i) the specific localization of a CNV within the 
11p15  region  (i.e the  CNV involves  key regulatory  elements  such as 
ICR2 in BWS patients with loss of methylation involving the centromeric 
domain or ICR1 in BWS and SRS patients with a DNA methylation defect 
of  the  telomeric  domain).  ii)  the  parental  transmission  of  the  CNV in 
familial cases: when inherited, a CNV inherited from a healthy parent was 
considered  as  potentially  pathogenic. iii)  copy-neutral  CNVs  (runs  of 
homozygosity) were considered as potentially pathogenic as losses and 
gains, as they might reflect segmental uniparental isodisomy. iv) variants 
that  are  seen  in  healthy  individuals  are  less  likely  to  account  for  a 
patient’s phenotype. To this purpose, the database of genomic variants 
(http://projects.tcag.ca/variation/) was consulted.
New  intermediate  CNVs  in  BWS  or  SRS  patients  with  DNA  
methylation defect at ICR1 or ICR2 
Six CNVs (2 deletions and 4 duplications) were identified in six patients, by 
using the cnvPartition v2.4.4 and/or the QuantiSNP v2.3 softwares (Table 
3). Three CNVs (4 to  22 kb)  were  only  identified with  the cnvPartition 
software and they were not confirmed by quantitative PCR. Three CNVs, 
all duplications, were identified with both softwares and were confirmed by 
quantitative real-time PCR. Those three validated duplications were further 
characterized. 
H47P BWS patient: 
The  male  patient  was  a  first  child,  born  after  38 weeks  of  gestation 
following  ovarian  stimulation.  Prenatal  sonography  identified  cystic 
hygroma  and  unilateral  pyelectasis.  Antenatal  karyotype  was  normal. 
There was no familial history of BWS. At birth, the patient displayed severe 
macrosomia (birth length 56 cm, +3.4 SD; birth weight 5490 g, +5.9 SD), 
macroglossia, umbilical hernia and facial dysmorphia and the first months 
of post-natal life were marked by feeding difficulties.  In early post-natal 
life,  the  patient  was  diagnosed  with  developmental  delay,  expressed 
primarily in the form of hypotonia and non-specific speech retardation. He 
walked  at  the  age  of  17  months.  He  underwent  pyeloplasty for 
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ureteropyelic junction stenosis at the age of 1 year and glossoplasty at the 
age of 3 years. Physical examination at the age of 51/12 years showed a 
slight  asymmetry  of  the  face,  lower  limbs  and  kidneys  and  advanced 
growth (+3.5 SD for height and +4.5 SD for weight).
Analysis of the 11p15 region showed a partial gain of methylation at ICR1 
[methylation index at 72% (normal: 53.9 ± 2%)] with a normal methylation 
status at ICR2 [methylation index at 45% (51.6 ± 2.5%)]. Analysis of SNP 
array data (Log R Ratio and B allele frequency)  identified a duplication 
(Figure  1A).  The  duplication  covered  the  whole  IGF2/H19 domain, 
involving  the  most  telomeric  probe  (position  1,970,084,  NCBI36/hg18 
Assembly), with a centromeric breakpoint located within the 3’ end of the 
CD81 gene  (between  position  2,374,469  and  2,375,108).  Quantitative 
PCR showed that the duplication extends to the telomeric end of the short 
arm (Figure 1B) refining the size of the duplication to approximately 2.4 
Mb. SNP analysis showed that the duplication involved the paternal allele 
(Figure 1C). CGH array confirmed the telomeric duplication at 11p15.5 and 
also identified a 2 Mb telomeric deletion at 11q25 (breakpoint  between 
position  132,431,292  and  134,432,465)  (Figure  1D).  Metaphase  FISH 
analysis of H47P with a 11p subtelomeric probe showed signals at both 
telomeres of a derivative chromosome 11, whereas FISH analysis using a 
11q  subtelomeric  probe  confirmed  a  deletion  of  11qter  by  showing  a 
fluorescent signal on the normal chromosome 11 only (Figure 1E). FISH 
analysis in parents identified a pericentric inversion in the father, with the 
11p  subtelomeric  probe  hybridizing  the  end  of  11q  and  the  11q 
subtelomeric  probe  hybridizing  the  end  of  11p  on  the  inverted 
chromosome (Figure 1E). As the size of the inverted segment is in the 
range of 130 Mb, the karyotypes were considered as normal in both H47P 
and  his  father  (data  not  shown).  This  observation  shows  that  partial 
trisomy  11p15  and  partial  monosomy  11q25  in  H47P  resulted  from 
unequal crossing over during paternal meiosis.
S72P SRS patient: 
The female patient  was the second child, conceived naturally  from  non 
consanguineous  parents  (Figure  2A).  At  birth  (term of  36  weeks),  she 
displayed intrauterine growth retardation [birth weight of 1690 g (-2.6 SD), 
10
29/7/11 
birth length of 39.5 cm (-4.4 SD)] with relative macrocephaly (-0.4 SD). 
Early postnatal life was marked by severe feeding difficulties and growth 
deceleration (-3 SD at the age by 7 months and -3.7 SD by the age of 15 
months) with a BMI of – 2 SD. SRS was diagnosed during the second year 
of life on the basis of postnatal growth retardation with conserved head 
circumference,  bossed  forehead,  clinodactyly  of  the  fifth  digits,  body 
asymmetry and feeding difficulties. The parents and the older brother were 
clinically normal and there was no familial history of SRS on the maternal 
side.
Analysis of the 11p15 region showed a partial loss of methylation at ICR1 
(methylation  index  at  25%)  with  a  normal  methylation  status  at  ICR2 
(methylation  index  at  47%).  Analysis  of  SNP  array  data  identified  a 
maternally-inherited  duplication  covering  part  of  the  IGF2/H19  domain, 
including  the  H19 gene and ICR1 but  not  the  IGF2 gene (Figure  2B). 
Characterization of the duplication by quantitative PCR and CGH array 
estimated its size between 562 and 575 kb with the telomeric breakpoint 
located between 1,522,259 and 1,530,602 bp (within the  HCCA2 gene) 
and the centromeric breakpoint located between 2,092,578 and 2,097,357 
bp (Figures 2C and 2D). Two color FISH analysis of S72P and her mother 
with two BAC probes (RP11-295K3 within the duplication and RP3-416J11 
outside the duplication) excluded an unbalanced translocation and showed 
an increased signal at 11p with RP11-295K3, providing indirect evidence 
for  cis-duplication  of  the  affected  region  (Figure  2E).  FISH  on  S72P’s 
interphased nuclei  clearly showed three hybridization signals confirming 
the cis-duplication (Figure 2F). Methylation analysis in the mother showed 
a gain of methylation at ICR1  (methylation index at 68%). The mother’s 
phenotype  was  normal  and  no  clinical  history  in  early  childhood  was 
indicative of BWS. Both maternal  grandparents had normal phenotypes 
and  there  was  no  familial  history  suggesting  SRS  or  BWS  cases. 
Assuming that the grand paternal allele was methylated in the mother, we 
performed  genomic  and  bisulfite  sequencing  of  the  ICR1  B6  repeat 
(1,980,297-1,980,616 bp) in S72P and her mother. An allelic imbalance 
was  observed  for  the  informative  rs61383602  SNP  in  the  mother, 
suggesting that the C allele was the duplicated allele (Figure 2 G). Bisulfite 
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sequencing showed that in the mother, the duplicated C allele peak was 
methylated  confirming that  the duplication  originated from the maternal 
grandfather (Figure 2G). 
Familial L65P BWS case: The family was previously reported as a clinical 
description  in  1983  29.  All  the  affected  subjects  were  conceived  from 
normal sisters (Figure 3A).  Patient L65P (III.7, Figure 3A) was born after 
40 weeks of a normal gestation from non consanguineous parents. The 
clinical  presentation  at  birth  included  macroglossia,  exomphalos, 
hypospadias, bilateral cryptorchidism, bilateral inguinal hernias,  posterior 
helical  pits and  severe  neonatal  hypoglycemia.  Patient  L65P  had  no 
macrosomia at birth (birth  weight  3200 gr,  -0.6 SD) but then displayed 
advanced growth (+ 2.5 SD at the age of 5 years) with a final height at 196 
cms (+ 2.8 SD). The familial history includes three other cases. The first 
pregnancy of individual II.1 was complicated at five months of gestation by 
acute hydramnios resulting in fetal death. Pathologic findings of the male 
fetus  (III.1)  included  exomphalos,  adrenal  cytomegaly  and  leydigian 
hyperplasia.  A  second  pregnancy  was  terminated  after  25  weeks  of 
gestation after  ultrasound examination showed an exomphalos. The first 
pregnancy  of  individual  II.4  was  also  terminated  after  18  weeks  of 
gestation after ultrasound diagnosis of exomphalos. Pathologic findings of 
the  female  fetus  (III.8)  included  exomphalos,  adrenal  cytomegaly  and 
ovarian  hyperplasia.  A  second  pregnancy  resulted  in  spontaneous 
abortion at 9 weeks. Analysis of the 11p15 region showed a complete loss 
of methylation at ICR2 in patient III.7 whereas the ICR2 methylation status 
in the mother (II.3) and her two sisters (II.1 and II.4), obligate carriers, was 
normal (Figure 3B). The ICR2 methylation pattern was also normal in the 
individuals whom DNA was available, including the maternal grandmother 
(Figure 3B). Search for a deletion involving ICR2 was negative (PCR and 
quantitative  PCR)  and  this  hypothesis  was  unlikely  as  the  ICR2  DNA 
methylation profile was normal in L65P’s mother and her sisters. ICR2 was 
also  sequenced  (position  2,677,063  to  2,679,536  bp) and  no  small 
deletions or mutations were identified. 
Analysis of SNP array and Log R Ratio data identified an approximately 50 
kb  duplication  ranging  from  approximately  2,485,000  to  2,533,000  bp 
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(Figure 3C), involving the 3’ part of intron 1, exon 2 and 5’ part of intron 2  
of the KCNQ1 gene (isoform NM000218.2). The duplication was confirmed 
by  quantitative  PCR  with  the  telomeric  breakpoint  located  between 
2,472,581  and  2,486,398  bp  and  the  centromeric  breakpoint  located 
between 2,526,347 and 2,540,424 bp  (Figure 3D).  The duplication was 
also found in the three sisters (obligate carriers) and also in unaffected 
individuals II.5 and III.5. Subject I.1 did not display the duplication (Figures 
3C and 3D), suggesting that the duplication was transmitted from L65P’s 
maternal grandfather (DNA not available) to the five siblings (II.1 to II.5). 
The duplication was also absent in the only unaffected child (III.3) born 
from one (II.1) of the three sisters (Figures 3A and 3D). FISH analysis with 
the CTD-2242D18 probe (position: 2,469,461-2,575,865) did not detect an 
increased hybridization signal on chromosome 11. It is likely that the small 
size of the duplication prevented its identification by FISH. The absence of 
an  extra  signal  on  another  chromosome  is  in  favor  of  a  11p15  cis-
duplication.
As the duplication encompasses two  CpG islands,  we investigated the 
methylation status of those CpG islands in three control subjects, L65P, 
his mother (II.3) and his maternal grandmother (I.1).  Bisulfite sequencing 
analysis of the CpG island in position  2,510,680-2,510,907 showed that 
both parental alleles were unmethylated (Figure 3F) in control  subjects, 
patient  L65P  and  subjects  II.3  and  I.1.  Analysis of  the  CpG island  in 
position  2,511,982-2,512,194  showed  that  the  CpG  island  was 
predominantly  methylated  with  no  allele-specific  DNA  methylation  in 
controls  (Figure  3F).  In  patient  L65P,  subjects  II.3  and  I.1,  the  DNA 
methylation pattern was the same as in control subjects.
Small CNVs in BWS patients with gain of DNA methylation at ICR1 
A few ICR1 deletions have been previously reported, essentially in BWS 
patients. They are small in the range of 1-2 kb and as they involve very 
few markers, they might be missed by the CNV detection methods. We 
therefore performed an accurate analysis of respective imprinting control 
regions  in  patients  with  abnormal  DNA  methylation  at  ICR1  or  ICR2, 
assuming that homozygous calls (B allele frequency) with a reduced copy 
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number (log R ratio) for SNPs mapping to ICR1 (1,976,000-1,981,000 bp) 
or  ICR2  (2,676,000-2,679,000  bp)  will  reflect  the  occurence  of  a 
hemizygous deletion.  
Three BWS patients with ICR1 gain of methylation displayed a low log R 
ratio for two or three SNPs located within ICR1 (Figure 4A). Two of them, 
H32P (previously reported, 18) and H50P presented as apparently sporadic 
BWS cases. H63P had a familial history of Wilms tumors on the maternal 
side (Figure 4B). H63P’s mother herself displayed a phenotype indicative 
of  BWS,  including  macrosomia  at  birth,  organomegaly  and  body 
asymmetry. She also developed a Wilms tumor when she was 5 years old. 
Deletions were characterized by long range PCR, quantitative PCR and 
sequencing  (Figures   4C,  4D  and  4E).  All  deletions  were  maternally-
inherited (Figure 4C). The two 1834 bp deletions (H32P and H50P) fusion 
blocks B6 with B3, removing two CTCF binding sites but involve different 
breakpoints (Figure 4F and Table 4). The 2240 bp H63P deletion fusions 
blocks B6 with B2 and removes CTCF binding sites 2, 3 and 4  (Figures 
4E, 4F and Table 4). 
No ICR1 deletion was detected in a series of 72 SRS patients displaying 
ICR1 loss of methylation. Similarly,  investigation of a large series of 78 
BWS with ICR2 loss of methylation did not identify any deletion.
Copy neutral CNVs 
Copy  neutral  CNVs  correspond  to  runs  of  homozygosity  without  any 
change in copy number. They might reflect uniparental isodisomy (UPiD) 
or  autozygosity.  UPiDs  previously  identified  in  BWS and  SRS patients 
involve both ICR1 and ICR2 and display a mosaic pattern. The density of 
the SNP array and the availability of  parental  DNA for 60% of patients 
made possible the identification of segmental UPiDs. Analysis of the data 
for shift in B allele frequency for heterozygous SNPs (not centered at 0.5), 
associated with a normal log R ratio and mendelian inconsistency (when 
parental DNA was available) did not identify mosaic segmental UPiD in 
SRS or BWS patients with loss or gain of DNA methylation at either ICR1 
or ICR2.
However, runs of homozygosity,  ranging from 86 to 335 kb (156 to 592 
14
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probes)  were  identified  in  the  various  groups  of  patients  and  controls 
(Figure 5). Although runs of homozygosity were identified within the whole 
11p15 region, two locations were overrepresented after analysis with the 
two  softwares. The  first  region  (position  2,170,000  to  2,270,000  bp), 
encompassing the paternally-imprinted ASCL2 gene, was homozygous in 
17% of both patients and controls (Box A in Figure 5 and supplementary 
Table  2).  The  second  region  (position  2,270,000  to  2,370,000  bp), 
encompassing the C11ORF21 and TSPAN32 genes, was homozygous in 
23% and 15% of patients and controls respectively (Box B in Figure 5 and 
supplementary Table 2).
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Discussion
Recent modifications to SNP arrays enhance the opportunity to discover 
CNVs along with  concomitant  SNP genotypes.  We designed a  custom 
SNP array to target the analysis  to the 11p15 region including the two 
imprinting  control  regions  and  investigate  whether  intermediate  lesions 
(which  cannot  be recognized by routine diagnostic  tools)  account  for a 
subset of 11p15 growth disorders with abnormal DNA methylation at either 
ICR1 or ICR2. A SNP array was favored to CGH array as it has the ability 
to (i)  simultaneously measure both intensity differences and allelic ratios 
and  therefore  to  investigate  both  DNA  copy-number  and  copy-neutral 
variation and (ii) identify the parental origin of CNVs. 
- We identified three novel duplications which have not been previously 
described.
Two duplications involved the IGF2/H19 domain. In the H47P BWS case, 
CGH showed that a 2 Mb deletion of the distal part of 11q was associated 
with  an apparently  de novo 2.4  Mb duplication of  the whole  IGF2/H19 
domain  on  the  paternal  chromosome.  FISH analysis  of  H47P  and  his 
parents demonstrated that H47P displayed recombination of a paternally-
inherited pericentric  inversion  of  chromosome 11,  with  a large inverted 
segment  of  approximately  130  Mb  (i.e  more  than  95%  of  the 
chromosome).  A  few  11p  pericentric  inversions  have  been  previously 
described  30-32,  some  of  them  with  a  predominant  BWS  phenotype  30. 
Those previously described pericentric inversions led to the duplication of 
the whole 11p15 imprinted domain with breakpoints between 11p13 and 
11p15.1. The H47P case is unique as the duplication of  the short  arm 
involves  only  part  of  the  11p15  imprinted  region  (i.e the  IGF2/H19 
domain). The deletion of 11q25 involves 10 genes  and might account for 
the developmental delay.
The  second  duplication  of  the  IGF2/H19 domain  represents  the  first 
observation of a genetic abnormality within the IGF2/H19 domain in SRS. 
The S72P cis-duplication involves only part of the IGF2/H19 domain (the 
imprinting  control  region  and  the  H19 gene)  and  results  in  a  SRS 
phenotype only if maternally-inherited when there is no phenotype upon 
paternal  transmission.  Both  the  parental  transmission  pattern  and  the 
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phenotype are different from previously reported ICR1 duplications 12, 33, 34. 
Cis-duplications  (0.3  to  1.8  Mb  in  size)  involving  the  whole  IGF2/H19 
domain  have  been  previously  reported  in  two  familial  12,  34 and  one 
sporadic  33 BWS cases.  They  resulted  in  a  BWS only  if  the  paternal 
chromosome  was  involved.  The  main  difference  between  the  S72P 
duplication and other duplications of the IGF2/H19 domain (12, 33, 34 and the 
H47P case) is that the S72P duplication involves ICR1 and the H19 gene 
but  does  not  involve  the  IGF2 gene.  Hence,  a  partial  maternal  cis-
duplication of the  IGF2/H19 domain results in a SRS phenotype (S72P 
case) whereas a maternal  cis-duplication involving the whole  IGF2/H19 
domain  does  not  result  in  any  phenotype  12 (Supplementary  figure  1). 
Although two copies of the active maternal  H19  gene are expressed in 
both  cases,  the  chromatin  organization  is  likely  to  be  different.  In  the 
partial  cis-duplication, one maternal  H19  gene is not engaged in a  cis-
effect. It  was recently shown that, apart from a  cis-effect, the  H19 non-
coding  RNA  also  regulates  the  expression  of  Igf2  by  a  transacting 
mechanism  35.  Indeed,  H19 transgenic expression is able to rescue the 
overgrowth phenotype of mice with targeted deletions of the H19 gene and 
also to reduce Igf2 expression 35. We hypothesize that an extra copy of a 
functional maternal H19 gene (not engaged in a cis-effect) can affect the 
expression  of  IGF2 by  a  transacting  mechanism  and  result  in  growth 
retardation.  Two  deletions  within  or  overlapping  the  S72P  duplicated 
region  have  been  registered  as  rare  variations,  in  apparently  normal 
subjects  (http://projects.tcag.ca/variation/;  variations  29891,  29893),  but 
the parental origin of these deletions are not known.
The  third  duplication  case  is  a  familial  BWS  case  with  ICR2  loss  of 
methylation,  involving  four  affected  subjects  conceived  from  three 
phenotypically  normal  sisters.  The  pattern  of  transmission  of  this  cis-
duplication  supports  its  pathogenicity  with  no  phenotype  when  the 
duplication  is  transmitted  through  the  male  germline  and  a  BWS 
phenotype  when  the  duplication  is  transmitted  through  the  female 
germline.  Moreover,  the  absence  of  the  duplication  in  an  unaffected 
subject  born  from  a  female  carrier  strengthens  the  significance  of  the 
duplication. Little  is  known on the  centromeric  11p15 imprinting  region 
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apart from the ICR2 imprinting control region. One deletion within the L65P 
duplicated  region  has  been  registered  as  a  rare  variation 
(http://projects.tcag.ca/variation/;  variation  29897) but the parental origin 
of this deletion is not known. Nevertheless, the 50 kb cis-duplication region 
displays evidence of open chromatin and encompasses two CpG islands 
and three CTCF binding sites. Analysis of the DNA methylation status of 
the  two CpG islands had not  been previously  documented.  Those two 
CpG  islands  are  not  allele-specific  differentially  methylated  in  control 
subjects,  with  one  being  predominantly  methylated  and  the  other  one 
unmethylated. In the patient displaying the cis-duplication, we showed that 
the  pattern  of  DNA  methylation  was  similar  to  the  pattern  of  control 
subjects.  The  location  of  the  duplication  also  corresponds  to  the 
centromeric breakpoint of a 1.8 Mb cis-duplication responsible for a BWS 
33
 and  the  Tm87-16  rhabdoid  tumor  translocation  breakpoint  within 
BWSCR1 36, 37. All together, this data strongly supports the relevance of the 
cis-duplication in the BWS phenotype and suggests that the cis-duplication 
affects  the  chromatin  conformation  and  impairs  the  apposition  and/or 
maintenance of DNA methylation at ICR2. 
- Precise analysis of the two imprinting control regions (ICR1 and ICR2) 
led to the identification of new small deletions. Those deletions were only 
identified in BWS patients with ICR1 gain of methylation. As for previous 
identified deletions  18,  the deletion breakpoints in those new cases map 
repetitive sequences within the B repeats of ICR1, suggesting that these 
repetitive sequences within ICR1 promote the risk of deletion. No ICR1 
deletions were identified in SRS patients with ICR1 loss of methylation and 
this  agrees  with  previous  publications  which  show  the  absence  of 
phenotype upon paternal transmission of ICR1 deletions  14,  16. Moreover, 
we did not identify  ICR2 deletions in this large series of BWS patients with 
ICR2 loss of methylation. Although ICR2 deletions (0.25 and 0.9 Mb) have 
been occasionally reported in BWS with loss of methylation at ICR2 19, 20, 
the data presented here establishes that they are extremely rare.
-  A  major  advantage  of  the  SNP  array  is  the  possibility  to  combine 
detection  of  gain/loss  CNVs  with  copy-neutral  CNVs  (runs  of 
homozygosity).  Such  segments  of  homozygosity  could  represent 
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uniparental isodisomy or autozygosity. Uniparental isodisomy is a classical 
cause of BWS and accounts for 20 to 25% of BWS cases 5 9, 10, whereas 
maternal isodisomy has been reported in only one SRS case 11. When the 
frequency of  uniparental isodisomy is well established in BWS, its extent 
on chromosome 11 has not been extensively analyzed.  In a recent study, 
Cooper et al. showed that the extent of isodisomy along chromosome 11 is 
variable but always involves the two 11p15.5 imprinted domains 10. In this 
study,  we  investigated  for  the  first  time  whether  smaller  uniparental 
isodisomies,  confined to one of the two 11p15 imprinted domains,  might 
account for DNA methylation defects restricted to ICR1 or ICR2. Although 
we identified runs of homozygosity in BWS and SRS patients, the B allele 
frequency was not indicative of mosaicism and there was no mendelian 
inconsistency when parental  DNA was  available.  This  data  shows  that 
segmental  uniparental  isodisomies confined  to  the  IGF2/H19 or  the 
KCNQ1OT1/CDKN1C domains  do  not  account  for  DNA  methylation 
defects restricted to one of the two 11p15 imprinted domains.
In summary, investigation by SNP array of a large series of BWS and SRS 
patients with isolated ICR1 or ICR2 DNA methylation defects led to the 
identification  of  new  molecular  defects  including  novel  segmental  cis-
duplications in both SRS and BWS patients and new ICR1 deletions in 
BWS  patients.  This  study  also  establishes,  for  the  first  time,  that 
segmental  uniparental  isodisomies do not  account  for  isolated ICR1 or 
ICR2 DNA methylation defects. We also demonstrate in a large series of 
BWS patients that ICR2 deletions are not a common mechanism for loss 
of methylation at ICR2.
 Our data also illustrates the difficulty of genetic counseling in patients with  
11p15 related growth disorders. Indeed, in more than 50% of cases, the 
clinical presentation was sporadic rather than familial despite a maternally-
inherited genetic defects. This study and a previous one 18 also emphasize 
that molecular defects in  cis are more common than initially thought in 
BWS patients with ICR1 gain of methylation and affect at least 20% of 
cases. 
Supplemental Data:
Supplemental Data include one figure and two tables and can be found 
19
29/7/11 
online at http://www.
Acknowledgments: 
We thank Annick Blaise for her technical assistance and the physicians for 
patients’  referrals and collection of  clinical  data. We are grateful  to  the 
willingness of the patients and their families to contribute to this study. 
Funding:
This work was supported by the National Health and Medical Research 
Council  of  Australia  (Project  grant  472637),  the  Baker  IDI  Heart  and 
Diabetes Institute,  the Institut  National  de la Santé et de la Recherche 
Médicale  UMPC  U938,  Université  Pierre  et  Marie  Curie  Paris  6  and 
Assistance Publique Hopitaux de Paris. 
Conflict of interest statement. None declared.
Web Resources:
The URLs for data presented herein are as follows:
Online  Mendelian  Inheritance  in  Man  (OMIM), 
http://www.ncbi.nlm.nih.gov/Omim/; International  HapMap  Project: 
http://www.hapmap.org/;  Database  of  genomic  variants: 
http://projects.tcag.  ca/variation;  UCSC  Genome  Browser,  March  2006 
build, http://genome. cse.ucsc.edu/
20
29/7/11 
References:
1. Reik, W., and Walter, J. (2001). Genomic imprinting: parental influence on 
the genome. Nat Rev Genet 2, 21-32.
2.  Delaval,  K.,  and  Feil,  R.  (2004).  Epigenetic  regulation  of  mammalian 
genomic imprinting. Curr Opin Genet Dev 14, 188-195.
3. Gicquel, C., and Le Bouc, Y. (2006). Hormonal regulation of fetal growth.  
Horm Res 65 Suppl 3, 28-33.
4.  Hudson,  Q.J.,  Kulinski,  T.M.,  Huetter,  S.P.,  and  Barlow,  D.P.  (2010). 
Genomic  imprinting  mechanisms  in  embryonic  and  extraembryonic  mouse 
tissues. Heredity. 105, 45-56.
5. Gaston, V., Le Bouc, Y.,  Soupre, V., Burglen, L., Donadieu, J., Oro, H., 
Audry, G., Vazquez, M.P., and Gicquel, C. (2001). Analysis of the methylation 
status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis 
and prognosis of Beckwith-Wiedemann syndrome. Eur J Hum Genet 9, 409-
418.
6. Cooper, W.N., Luharia, A., Evans, G.A., Raza, H., Haire, A.C., Grundy, R., 
Bowdin,  S.C.,  Riccio,  A.,  Sebastio,  G.,  Bliek,  J.,  et  al.  (2005).  Molecular 
subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur 
J Hum Genet 13, 1025-1032.
7. Gicquel, C., Rossignol, S., Cabrol, S., Houang, M., Steunou, V., Barbu, V., 
Danton, F., Thibaud, N., Le Merrer, M., Burglen, L., et al. (2005). Epimutation 
of  the  telomeric  imprinting  center  region  on chromosome 11p15 in  Silver-
Russell syndrome. Nat Genet 37, 1003-1007.
8.  Weksberg,  R.,  Shuman,  C.,  and  Beckwith,  J.B.  (2010).  Beckwith-
Wiedemann syndrome. Eur J Hum Genet 18, 8-14.
9.  Henry,  I.,  Bonaiti-Pellie,  C.,  Chehensse,  V.,  Beldjord,  C.,  Schwartz,  C., 
Utermann, G., and Junien, C. (1991). Uniparental paternal disomy in a genetic 
cancer-predisposing syndrome. Nature 351, 665-667.
10. Cooper, W.N., Curley, R., Macdonald, F., and Maher, E.R. (2007). Mitotic 
recombination  and  uniparental  disomy  in  Beckwith-Wiedemann  syndrome. 
Genomics 89, 613-617.
11. Bullman, H., Lever, M., Robinson, D.O., Mackay, D.J., Holder, S.E., and 
Wakeling, E.L. (2008). Mosaic maternal uniparental disomy of chromosome 
11 in a patient with Silver-Russell syndrome. J Med Genet 45, 396-399.
21
29/7/11 
12. Bliek, J., Snijder, S., Maas, S.M., Polstra, A., van der Lip, K., Alders, M., 
Knegt,  A.C.,  and  Mannens,  M.M.  (2009).  Phenotypic  discordance  upon 
paternal  or  maternal  transmission  of  duplications  of  the  11p15  imprinted 
regions. Eur J Med Genet 52, 404-408.
13. Netchine, I., Rossignol, S., Dufourg, M.N., Azzi, S., Rousseau, A., Perin, 
L.,  Houang, M.,  Steunou, V.,  Esteva, B.,  Thibaud, N., et  al.  (2007). 11p15 
imprinting center region 1 loss of methylation is a common and specific cause 
of  typical  Russell-Silver  syndrome:  clinical  scoring  system  and  epigenetic-
phenotypic correlations. J Clin Endocrinol Metab 92, 3148-3154.
14. Sparago, A., Cerrato, F., Vernucci, M., Ferrero, G.B., Silengo, M.C., and 
Riccio, A. (2004). Microdeletions in the human H19 DMR result in loss of IGF2 
imprinting and Beckwith-Wiedemann syndrome. Nat Genet 36, 958-960.
15. Prawitt, D., Enklaar, T., Gartner-Rupprecht, B., Spangenberg, C., Oswald, 
M., Lausch, E., Schmidtke, P., Reutzel, D., Fees, S., Lucito, R., et al. (2005). 
Microdeletion  of  target  sites  for  insulator  protein  CTCF in  a  chromosome 
11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. 
Proc Natl Acad Sci U S A 102, 4085-4090.
16.  Sparago,  A.,  Russo,  S.,  Cerrato,  F.,  Ferraiuolo,  S.,  Castorina,  P., 
Selicorni, A., Schwienbacher, C., Negrini, M., Ferrero, G.B., Silengo, M.C., et  
al.  (2007).  Mechanisms  causing  imprinting  defects  in  familial  Beckwith-
Wiedemann syndrome with Wilms' tumour. Hum Mol Genet 16, 254-264.
17. Scott, R.H., Douglas, J., Baskcomb, L., Huxter, N., Barker, K., Hanks, S., 
Craft, A., Gerrard, M., Kohler, J.A., Levitt, G.A., et al. (2008). Constitutional 
11p15 abnormalities,  including heritable imprinting center  mutations, cause 
nonsyndromic Wilms tumor. Nat Genet 40, 1329-1334.
18. Demars, J., Shmela, M.E., Rossignol, S., Okabe, J., Netchine, I., Azzi, S., 
Cabrol, S., Le Caignec, C., David, A., Le Bouc, Y., et al. (2010). Analysis of 
the  IGF2/H19  imprinting  control  region  uncovers  new  genetic  defects, 
including mutations of OCT-binding sequences, in patients with 11p15 fetal 
growth disorders. Hum Mol Genet 19, 803-814.
19.  Niemitz,  E.L.,  DeBaun,  M.R.,  Fallon,  J.,  Murakami,  K.,  Kugoh,  H., 
Oshimura,  M.,  and Feinberg,  A.P.  (2004).  Microdeletion of  LIT1 in  familial 
Beckwith-Wiedemann syndrome. Am J Hum Genet 75, 844-849.
20. Zollino, M., Orteschi, D., Marangi, G., De Crescenzo, A., Pecile, V., Riccio, 
22
29/7/11 
A., and Neri, G. (2010). A case of Beckwith-Wiedemann syndrome caused by 
a cryptic 11p15 deletion encompassing the centromeric imprinted domain of 
the BWS locus. J Med Genet 47, 429-432.
21. Rossignol, S., Steunou, V., Chalas, C., Kerjean, A., Rigolet, M., Viegas-
Pequignot,  E.,  Jouannet,  P.,  Le  Bouc,  Y.,  and  Gicquel,  C.  (2006).  The 
epigenetic imprinting defect of patients with Beckwith-Wiedemann syndrome 
born  after  assisted  reproductive  technology  is  not  restricted  to  the  11p15 
region. J Med Genet 43, 902-907.
22. Azzi, S., Rossignol, S., Steunou, V., Sas, T., Thibaud, N., Danton, F., Le 
Jule,  M.,  Heinrichs,  C.,  Cabrol,  S.,  Gicquel,  C.,  et  al.  (2009).  Multilocus 
methylation analysis in a large cohort of 11p15-related foetal growth disorders 
(Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous 
loss of methylation at paternal and maternal imprinted loci. Hum Mol Genet 
18, 4724-4733.
23. Bliek, J., Alders, M., Maas, S.M., Oostra, R.J., Mackay, D.M., van der Lip, 
K., Callaway, J.L., Brooks, A., van 't Padje, S., Westerveld, A., et al. (2009). 
Lessons from BWS twins:  complex maternal  and paternal  hypomethylation 
and a common source of haematopoietic stem cells. Eur J Hum Genet  17, 
1625-1634.
24. Bliek, J., Verde, G., Callaway, J., Maas, S.M., De Crescenzo, A., Sparago, 
A.,  Cerrato,  F.,  Russo,  S.,  Ferraiuolo,  S.,  Rinaldi,  M.M.,  et  al.  (2009). 
Hypomethylation at multiple maternally methylated imprinted regions including 
PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet 
17, 611-619.
25. Lim, D., Bowdin, S.C., Tee, L., Kirby, G.A., Blair, E., Fryer, A., Lam, W., 
Oley, C., Cole, T., Brueton, L.A., et al. (2009). Clinical and molecular genetic 
features  of  Beckwith-Wiedemann  syndrome  associated  with  assisted 
reproductive technologies. Hum Reprod 24, 741-747.
26. Meyer, E., Lim, D., Pasha, S., Tee, L.J., Rahman, F., Yates, J.R., Woods, 
C.G.,  Reik,  W.,  and  Maher,  E.R.  (2009).  Germline  mutation  in  NLRP2 
(NALP2) in a familial  imprinting disorder (Beckwith-Wiedemann Syndrome). 
PLoS Genet 5, e1000423.
27.  Colella,  S.,  Yau,  C.,  Taylor,  J.M.,  Mirza,  G.,  Butler,  H.,  Clouston,  P., 
Bassett, A.S., Seller, A., Holmes, C.C., and Ragoussis, J. (2007). QuantiSNP: 
23
29/7/11 
an Objective Bayes Hidden-Markov Model to detect and accurately map copy 
number variation using SNP genotyping data. Nucleic Acids Res  35, 2013-
2025.
28. Dellinger, A.E., Saw, S.M., Goh, L.K., Seielstad, M., Young, T.L., and Li, 
Y.J.  (2010).  Comparative  analyses  of  seven  algorithms  for  copy  number 
variant  identification  from  single  nucleotide  polymorphism  arrays.  Nucleic 
Acids Res 38, e105.
29. Nivelon-Chevallier, A., Mavel, A., Michiels, R., and Bethenod, M. (1983). 
[Familial Wiedeman-Beckwith syndrome: prenatal echography diagnosis and 
histologic confirmation]. J Genet Hum 31 Suppl 5, 397-402.
30. Waziri, M., Patil, S.R., Hanson, J.W., and Bartley, J.A. (1983). Abnormality 
of  chromosome  11  in  patients  with  features  of  Beckwith-Wiedemann 
syndrome. J Pediatr 102, 873-876.
31. Stratakis, C.A., Turner, M.L., Lafferty, A., Toro, J.R., Hill, S., Meck, J.M., 
and Blancato, J. (2001). A syndrome of overgrowth and acromegaloidism with 
normal  growth  hormone  secretion  is  associated  with  chromosome  11 
pericentric inversion. J Med Genet 38, 338-343.
32. Gadzicki, D., Baumer, A., Wey, E., Happel, C.M., Rudolph, C., Tonnies, 
H., Neitzel, H., Steinemann, D., Welte, K., Klein, C., et al. (2006). Jacobsen 
syndrome  and  Beckwith-Wiedemann  syndrome  caused  by  a  parental 
pericentric inversion inv(11)(p15q24). Ann Hum Genet 70, 958-964.
33. Russo, S., Finelli,  P.,  Recalcati,  M.P., Ferraiuolo, S., Cogliati,  F.,  Dalla 
Bernardina, B., Tibiletti, M.G., Agosti, M., Sala, M., Bonati, M.T., et al. (2006). 
Molecular and genomic characterisation of  cryptic  chromosomal  alterations 
leading to paternal duplication of the 11p15.5 Beckwith-Wiedemann region. J 
Med Genet 43, e39.
34. Algar, E.M., St Heaps, L., Darmanian, A., Dagar, V., Prawitt, D., Peters,  
G.B., and Collins, F. (2007). Paternally inherited submicroscopic duplication at 
11p15.5  implicates  insulin-like  growth  factor  II  in  overgrowth  and  Wilms' 
tumorigenesis. Cancer Res 67, 2360-2365.
35. Gabory, A., Ripoche, M.A., Le Digarcher, A., Watrin, F., Ziyyat, A., Forne, 
T., Jammes, H., Ainscough, J.F., Surani, M.A., Journot, L., et al. (2009). H19 
acts as a trans regulator of the imprinted gene network controlling growth in 
mice. Development 136, 3413-3421.
24
29/7/11 
36. Lee, M.P.,  Hu, R.J., Johnson, L.A., and Feinberg, A.P. (1997). Human 
KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-
Wiedemann syndrome chromosomal rearrangements. Nat Genet 15, 181-185.
37.  Prawitt,  D.,  Enklaar,  T.,  Klemm,  G.,  Gartner,  B.,  Spangenberg,  C., 
Winterpacht, A., Higgins, M., Pelletier, J., and Zabel, B. (2000). Identification 
and  characterization  of  MTR1,  a  novel  gene  with  homology  to  melastatin 
(MLSN1) and the trp gene family located in the BWS-WT2 critical region on 
chromosome 11p15.5 and showing allele-specific expression. Hum Mol Genet 
9, 203-216.
38.  Schonherr,  N.,  Meyer,  E.,  Roos,  A.,  Schmidt,  A.,  Wollmann, H.A.,  and 
Eggermann,  T.  (2007).  The  centromeric  11p15  imprinting  centre  is  also 
involved in Silver-Russell syndrome. J Med Genet 44, 59-63.
25
29/7/11 
Figures titles and legends:
Figure 1: ICR1 duplication resulting from recombination of a paternal 
pericentric inversion in a BWS patient with ICR1 gain of methylation
 (A) Graphical overview of B allele frequency and log R Ratio obtained 
from the SNP array in H47P and his parents, showing a duplication of the 
IGF2/H19 domain in H47P. The location of the duplication is highlighted by 
the grey box. (B) Genomic real-time PCR quantification assay at various 
loci along the IGF2/H19 domain validating the duplication. (C) Sequencing 
at  various  informative  SNPs  within  the  duplication  showing  that  the 
duplication involves the paternally-inherited allele. (D) Graphical overview 
of the results obtained from the array-CGH analysis of H47P, showing a 
distal  11p duplication and a distal  11q deletion.  (E)  FISH analysis  with 
subtelomeric  probes  for  11p  (green)  and  11q  (red).  The  normal 
chromosome 11  has  one  green  and  one  red  signal  for  11p  and  11q, 
respectively.  In  H47P,  the recombinant  chromosome 11 [rec(11)  dup p 
inv(11)]  has green signals for  11p on both ends and no red signal.  In 
H47P’s father, the inverted chromosome 11 [inv(11) p15.5q25] has a red 
signal  on 11p and a green signal on 11q. Small white arrows indicate the 
centromeres.
Figure 2: Familial ICR1 duplication in a SRS patient with ICR1 loss of 
methylation
(A) Pedigree of the S72P SRS case. (B) Graphical overview of B allele 
frequency and log R Ratio obtained from the SNP array in S72P and her 
parents,  showing a maternally-inherited segmental duplication of part of 
the  IGF2/H19  domain  in  S72P.  The  location  of  the  duplication  is 
highlighted by the  grey  box.  (C)  Genomic  real-time  PCR quantification 
assay at various loci along the IGF2/H19 domain validating the duplication 
in S72P and her mother. (D) Graphical overview of the results obtained 
from  the  array-CGH  analysis  of  S72P.  The  duplication  interval   (from 
1,530,602  to  2,092,578  bp)  is  underlined  with  the  pink  rectangle.  (E) 
Partial  metaphases  of  patient  S72P.  FISH  with  the  BAC probe  RP11-
295K3  within  the  duplication  shows  an  increased  hybridization  signal 
(green signal) on one of the chromosomes 11 (arrow) when the signal with  
the BAC probe RP3-416J11 outside the duplication (red signal) is similar 
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on both chromosomes. (F)  FISH on S72P’s interphased nuclei  with  the 
BAC probe RP11-295K3 shows three hybridization signals confirming the 
duplication.  (G) Chromatograms  of  the  ICR1  B6  repeat  including  SNP 
rs61383602 (framed in red) before and after bisulfite treatment for patient 
S72P  and  her  mother.  After  bisulfite  treatment,  patient  S72P  (non 
informative for the polymorphism) displays a T allele peak (unmethylated 
duplicated  maternal  allele)  higher  than  the  C  allele  peak  (methylated 
paternal allele). In the mother, informative for the polymorphism, before 
treatment  by  bisulfite,  the  C  allele  peak  is  higher  than  the  T  allele 
confirming the duplication. The profile is the same after bisulfite treatment 
showing  that  the  C  methylated  allele  was  inherited  from  the  maternal 
grandfather. 
Figure 3: Familial ICR2 BWS case
(A) Pedigree of the familial BWS case and segregation. Subjects identified 
with  the  duplication  are  indicated  with  a  star.  SB:  stillbirth.  (B)  DNA 
methylation at ICR2, assayed by methyl-sensitive Southern blotting using 
genomic DNA from the indicated individuals.  The upper band (6 kb)  is 
methylated and corresponds to the maternal allele. The lower band (4.2 
kb)  is  unmethylated  and corresponds to  the paternal  (ICR2) allele. (C) 
Graphical overview of log R Ratio results obtained from the SNP array in 
L65P (III.7), his mother (II.3) and maternal grandmother (I.1), showing a 
maternally-inherited duplication in L65P and his mother. The location of 
the duplication is highlighted by the grey box. (D) Genomic real-time PCR 
quantification assay at several loci along the ICR2 domain validating the 
duplication. (E) DNA methylation profiles of the two CpG islands included 
in  the  cis-duplication  determined  by  bisulfite  sequencing  in  a  control 
subject,  the  propositus  (L65P/III.7), his  mother  (II.3)  and  maternal 
grandmother  (I.1).  Each  line  corresponds  to  an  individual  cloned  DNA 
fragment and each circle represents a CpG dinucleotide. Methylated CpGs 
are indicated by filled  circles  and unmethylated  CpGs by open circles. 
Parental  alleles  were  distinguished  by  the  rs179436  nucleotide 
polymorphism for the 2,510,680-2,510,907 CpG island and the rs2074247 
nucleotide polymorphism for the 2,511,982-2,512,194 CpG island. The 16 
and 17 CpG islands are framed. 
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Figure  4:  ICR1  deletions  in  BWS  patients  with  ICR1  gain  of 
methylation
 (A) Graphical overview of log R ratio results focused at ICR1 obtained 
from the SNP array in BWS cases H50P and H63P; location of deletions 
identified  by log  R ratio  values are  underlined with  a black  arrow.  (B) 
Pedigree  of  the  familial  H63P  BWS  case  and  segregation.  Subjects 
identified  in  grey  developed  Wilms  tumors.  (C)  Agarose  gel  of  PCR 
amplifications (position 1,976,966 to  1,981,302 bp)  showing maternally-
inherited  deletions  in  H50P  and  H63P families.  (D)  Genomic  real-time 
PCR quantification assay at two loci within the ICR1 domain confirmed the 
deletions in patients H50P and H63P. (E) Position of the breakpoints of 
H63P’s deletion (at 1,978,248 -1,978,293 bp and 1,980,488-1,980,533 bp) 
have been identified after sequencing both alleles and are highlighted on 
the chromatograms. The deletion removes three CTCF binding sites (2, 3 
and  4).  (F)  Localization  of  ICR1  deletions  identified  in  this  study  and 
deletions previously described 15-17.
Figure 5: Runs of homozygosity identified in control subjects and patients. 
Vertical  lines represent  length  of  homozygous  regions.  The black,  light 
blue, dark blue and red colors represent control subjects, BWS patients 
with ICR1 gain of methylation, BWS patients with ICR2 loss of methylation 
and SRS patients with a loss of methylation, respectively. The A light grey 
box underlines the region encompassing the paternally-imprinted  ASCL2 
gene.  The  B  dark  grey  box  underlines  the  region  encompassing  the 
C11ORF21 and TSPAN32 genes. 
Supplementary figure 1: Schematic diagram of the 11p15 region with a 
summary  of  the  duplications  identified  in  the  cohort  and  duplications 
previously described 12, 33, 34, 38.
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Table  1:  Clinical  and  molecular  features  of  patients  with  Beckwith-
Wiedemann syndrome
BWS with ICR2 
loss of methylation
BWS with ICR1
gain of methylation
n 78 35
sex F/M 36/42 17/18
gestational agea, weeks mean ± SD; (range) 36.2 ± 3.2 (27-41) 36.7 ±  3.1 (30-40)
ART, n 9 1
monozygotic twins 7 0
fetal cases 6 3
familial cases 1 4c
phenotype
macrosomia at birthb, n (%) 31/65 (48%) 24/35 (69%)
birth weight (SDS) 1.7 ± 1.6 2.8 ± 1.9
macroglossia, n (%) 75/77 (97.5%) 31/33 (94%)
abdominal wall defect, n (%) 54/77 (70%) 20/32 (62%)
diastasis recti, n (%) 4 12
umbilical hernia, n (%) 21 7
exomphalos, n (%) 29 1
organomegaly, n (%) 33/69 (48%) 24/32 (75%)
body asymmetry, n (%) 20/71 (28%) 12/33 (36%)
hypoglycaemia, n (%) 26/63 (41%) 9/30 (30%)
ear abnormalities, n (%) 54/74 (73%) 9/30 (30%)
tumour, n (%) 0/71 (0%) 8/32 (25%)d
others
ICR1 MI, mean ± (SD)
(N=53.9 ± 2%)
52.8 ± 4.1 76 ± 10.3
ICR2 MI, mean ± (SD)
(N=51.6 ± 2.5%)
8.5 ± 7.7 47.9 ± 3.8
parental DNA, n(%) 62/78 (79.5%) 18/35 (51%)
Both parents  57 14
One parent 5 4
a: gestational age is in weeks of amenorrhea
b: twins not included
c: 4 subjects from 2 families (two siblings in one family and a son and his 
mother in the other family)
d: all tumors were Wilms tumors
ART: assisted reproductive technology; MI: methylation index
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Table 2: Clinical and molecular features of patients with Silver-Russell 
syndrome
SRS with ICR1 
loss of methylation
n 72
sex F/M 25/47
gestational agea, weeks 38.2 ± 2
ART, n 6
monozygotic twins 3
phenotype
IUGR, n (%) 66/68 (97%)
birth weight (SDS) b -3.1 ± 0.7
post-natal growth retardation, n (%) 61/64 (95%)
relative macrocephaly at birth, n (%) 59/62 (95%)
facial dysmorphy, n (%) 49/57 (86%)
body asymmetry, n (%) 51/68 (75%)
feeding difficulties, n (%) 47/63 (75%)
severe, n 16
moderate, n 31
BMI (SDS) -2.2 ± 1.1
BMI ≤ -2 SDS 40/59 (69%)
developmental delay, n (%) 9/57 (16%)
clinodactyly, n (%) 51/61 (84%)
others
ICR1 MI, mean ± (SD)
(N=53.9 ± 2%)
23 ± 8.3
ICR2 MI, mean ± (SD)
(N=51.6 ± 2.5%)
47.6 ± 4.1
parental DNA, n(%) 30 (39%)
both parents 22
one parent 8
a: gestational age is in weeks of amenorrhea
b: twins not included
ART: assisted reproductive technology; IUGR: intrauterine growth retardation; 
MI: methylation index
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Table 3: Copy number variations detected in SRS and BWS patients with cnvPartition v2.4.4 and QuantiSNP v2.3 softwares
patients patients’ group CNV type origin parental
chromosome
size
kb
markers
n
 detection cnvPartition/
confidence score
detection QuantiSNP /
Log Bayes Factor
qPCR
validation
H4P BWS ICR1 duplicatio
n
NA* / 22 15 yes/45.74 no no
H47P BWS ICR1 duplicatio
n
de novo paternal 400** 526 yes/1900.99 yes/30.33 yes
L65P BWS ICR2 duplicatio
n
inherited maternal 50 78 yes/232.11 yes/63.94 yes
L263P BWS ICR2 deletion de novo maternal 4.4 3 yes/73.93 no no
S63P SRS ICR1 deletion de novo paternal 4 3 yes/230.73 no no
S72P SRS ICR1 duplicatio
n
inherited maternal 80** 89 yes/398.29 yes/44.24 yes
* NA: parental DNA not available
** These CNVs include the most telomeric probe of the OPA.
BWS ICR1: BWS patients with ICR1 gain of methylation. BWS ICR2: BWS patients with ICR2 loss of methylation. SRS ICR1:  
SRS patients with ICR1 loss of methylation.
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Table 4: Characterization of ICR1 deletions in BWS patients with ICR1 gain of methylation
familial history size (bp) breakpoints fused repeats deleted CTCF 
binding sites
H32P no 1834 1978828-1978846/1980662-1980680 B6/B3 2, 3
H50P no 1834 1978576-1978605 /1980411-1980431 B6/B3 3, 4
H63P yes 2240 1978248 -1978293/1980488-1980533 B6/B2 2, 3, 4
* Genomic positions were assigned according to the data provided by the UCSC genome browser (hg18, NCBI 36)
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Supplementary table 1: Additional primers used in this study
Name Localization hg18 (bp) Sequence forward Sequence reverse Use
hg18_chr11_499934/500052 499934-500052 GAAGTATTCCCACCCCCAGT CAGATCTGTGTGGAGCAGGA CNV validation H47P, qPCR
hg18_chr11_1000151/1000289 1000151-1000289 TCCCAGCTGTTCCTCTCTGT TGCAGCACTAACCACACACA CNV validation H47P, qPCR
hg18_chr11_1499784/1499923 1499784-1499923 TCTAAGGCTTGGGGTTTTCC ACAGCTCGTCCCGTAGAAGA CNV validation H47P and S72P, qPCR
hg18_chr11_1960213/1960314 1960213-1960314 GAGGCAAGATTTGGAAACGA CTGGGCAGGAGACTCTGATT CNV validation H47P and S72P, qPCR
hg18_chr11_1977096/1977030 1977096-1977030 ACGTGGAGAGGTGAATTTGC TCCTGCTCCAGGCATTGT CNV validation H47P and S72P, qPCR
hg18_chr11_2123897/2124137 2123897-2124137 AAACCCACATTCCACAGAGG TCTGAGGACCCTTGGAGAAA CNV validation H47P, qPCR
hg18_chr11_2370152/2370254 2370152-2370254 GGCAGAAGCAGAGGTCACA ACACCATGCAGGTCAGACAC CNV validation H47P, qPCR
hg18_chr11_2375108/2375201 2375108-2375201 CCTTCATGCACCTGTCCTTT GCATGCCTGATGTTCCTTCT CNV validation H47P, qPCR
hg18_chr11__2155877/2156345 2155877-2156345 AGGGAAGGGGATCCAGTG CAGACACAGACCAGCGAAAA CNV validation H47P, Parental origin
hg18_chr11_2371018/2371497 2371018-2371497 CTGCTGAGGGATAGGGGAGT AGTGGCATCAGAAGGCACAG CNV validation H47P, Parental origin
hg18_chr11_2191887/2192349 2191887-2192349 GTTCCTCCTGCCTCCCTAAC AGAGCGGGGAAGAAACAGAT CNV validation H47P, Parental origin
hg18_chr11_2035226/2035462 2035226-2035462 CCTCGATAGCCATTTTGCAT GCATGGCAAAAGGAGAAAAG CNV validation S72P, qPCR
hg18_chr11_2107371/2107558 2107371-2107558 GCTTCTGGGTCCTGGTGAC CTCGAAGCGTTTTGGATCTC CNV validation S72P, qPCR
hg18_chr11_1980297/1980616 1980297-1980616 AGGTGTTTTAGTTTTTTGGATGATA CCATAAATATTCTATCCCTCACTA CNV validation S72P, Bisulfite treatment
hg18_chr11_2486398/2486518 2486398-2486518 AGGACCCAGACTCCCAGAC AGGTGGTCACTGCCATCTTC CNV validation L65P, qPCR
hg18_chr11_2540424/2540567 2540424-2540567 CTGTGTCCACCCCTCTTCAG ACTTAGGCCTGGGGACCTT CNV validation L65P, qPCR
hg18_chr11_2526198/2526347 2526198-2526347 TCGGTCAGGTTAGTTGCTGT CCCCCAGAGCTTAGGACACT CNV validation L65P, qPCR
hg18_chr11_2472491/2472581 2472491-2472581 GAAGCCCACTTGATCACCAT GAGCACCGATGCAAAAATCT CNV validation L65P, qPCR
hg18_chr11_2676672/2677949 2676672-2677949 TGGGACCCCAACTACTCAGA AGGACACGGCACATCACTTT CNV validation L65P, sequencing
hg18_chr11_2677793/2679793 2677793-2679793 ACCGTTCTGCCTGGAGACTG GCCACCCTCAACTCAACATT CNV validation L65P, sequencing
hg18_chr11_2510633/2510968 2510633-2510968 GGTTTTTGATTTTAGTAGAGGGAGG AAACAAAAACTCCCTAAAAACACAT CNV validation L65P, Bisulfite treatment
hg18_chr11_2511951/2512483 2511951-2512483 AGTGAGATTTTGTAGGGAGTTTTTG AACCCACAAAAAAACACAACTCT CNV validation L65P, Bisulfite treatment
hg18_chr11_2674923/2675237 2674923-2675237 GGAGTAGGCCAAGGATGTCA GAGTTTTCCAGAGGCAGCAC deletion ICR2 L65P, qPCR
hg18_chr11_2649043/2649262 2649043-2649262 GACCTCAAAATCCGATGTCC GGTTGCTCTTCTGCCTGCTA deletion ICR2 L65P, qPCR
hg18_chr11_1978454/1978696 1978454-1978696 ATGTGGCTCCCATGAATGTC GGCTCTTGCATAGCACATGA deletions ICR1 H50P and H63P, qPCR
hg18_chr11_1979289/ 1979612 1979289-1979612 CTGATTCCAGCAGCACAGAG TCAGTGCAGGTTTGAGATGC deletions ICR1 H50P and H63P, qPCR
hg18_chr5_134898593/134898695 134898593-134898695 GCTCTCTGACCCCAGTAGCC TGTGTGGAGCAAGTCTTTGG housekeeping gene, qPCR
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Supplementary table 2: Runs of homozygosity detected in control subjects 
and patients
Sample id. Start Position (bp) End Position (bp) Length (bp) Probes (n) Score  Max. Log BF
Control samples
CS_107 2264880 2381611 116732 210 37.1696
CS_154 2155554 2261555 106002 195 32.2554
CS_187 2559602 2690701 131100 195 34.3885
CS_189 2283188 2381611 98424 168 30.3942
CS_19 2128498 2346891 218394 408 101.166
CS_205 2128498 2261555 133058 257 45.1774
CS_245 2159621 2261078 101458 185 35.3047
CS_254 2155554 2262744 107191 199 33.8643
CS_300 2155554 2347625 192072 349 62.0078
CS_300 2780921 2869522 88602 176 42.9269
CS_315 2233543 2381611 148069 278 37.1292
CS_365 2233543 2529468 295926 507 62.7432
CS_370 2707910 2816117 108208 207 38.2093
CS_375 2264880 2381611 116732 210 40.529
CS_415 2412354 2537338 124985 188 37.1774
CS_7 2156905 2267446 110542 205 30.2087
CS_D 2165989 2381611 215623 394 59.2346
ICR1 GOM BWS
AA30P 2283727 2479634 195908 302 32.303
H12P 2286571 2381611 95041 158 30.3052
H20P 2285283 2381284 96002 161 34.5552
H23P 2283727 2425532 141806 239 33.3802
H29P 2176538 2387096 210559 381 72.3474
H2P 2151386 2261555 110170 203 42.128
H2P 2291307 2387096 95790 159 39.9038
H43P 1970084 2177516 207433 358 78.7391
H43P 2273296 2389540 116245 209 49.8905
H43P 2409470 2597296 187827 290 61.554
H44P 2156905 2381611 224707 407 90.1299
H54P 2181257 2267728 86472 156 40.1736
H55P 2206725 2381611 174887 312 43.1212
H61P 2283727 2385251 101525 172 31.1806
H61P 2644661 2782775 138115 264 53.5701
H69P 2511521 2708236 196716 304 40.6492
H6P 2047032 2381611 334580 592 152.827
H70P 2505433 2690701 185269 289 39.761
H8P 2144814 2261555 116742 217 49.5353
ICR2 LOM BWS
41P 2138346 2381611 243266 449 91.8929
41P 2423780 2597296 173517 269 31.3046
L101P 2156905 2381611 224707 406 88.2207
L110P 2073262 2261555 188294 344 78.5962
L113P 2191119 2387441 196323 342 71.585
L116P 2206725 2381284 174560 312 45.4417
L119P 2497741 2720353 222613 354 65.004
L134P 2582824 2751568 168745 270 34.6159
L138P 2716781 2869522 152742 295 52.1911
L151P 2173007 2262744 89738 167 31.3149
L164P 2165989 2381284 215296 393 75.3495
L167P 2399757 2584063 184307 290 54.5854
L170P 2150393 2272679 122287 226 50.2314
L173P 2285283 2388145 102863 175 35.2167
L177P 2283188 2387096 103909 179 35.2186
L177P 2559602 2720353 160752 248 40.4669
L186P 2185285 2387096 201812 363 60.9426
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L190P 2264880 2387096 122217 221 44.6633
L196P 2264880 2387096 122217 221 45.4819
L1P 2156905 2347625 190721 346 47.3695
L203P 2264880 2388145 123266 223 41.479
L20P 2283188 2387096 103909 179 33.5019
L214P 2250529 2529468 278940 472 101.227
L246P 2283727 2381611 97885 166 30.5518
L262P 2270670 2381611 110942 200 35.9644
L278P 2250529 2381611 131083 244 49.4586
L39P 2126011 2261555 135545 266 38.9765
L39P 2393143 2505833 112691 169 33.0644
L42P 2168253 2381611 213359 390 72.101
L49P 2176538 2267728 91191 168 30.8099
L4P 2000375 2191705 191331 332 44.9354
L4P 2233543 2381611 148069 278 36.2062
L4P 2652083 2764038 111956 206 39.2673
L58P 2176538 2288613 112076 220 46.4965
L95P 2039703 2262744 223042 386 111.035
ICR1 LOM SRS
S103P 2049559 2192166 142608 263 63.3619
S41P 2060139 2177516 117378 217 55.3193
S29P 2104733 2192830 88098 203 32.0159
S5P 2130774 2261555 130782 252 48.5926
S122P 2133080 2241585 108506 207 36.0915
S129P 2137348 2246000 108653 205 30.2934
S72P 2149268 2261555 112288 208 42.3326
S116P 2155554 2261555 106002 194 41.4788
S107P 2156905 2267446 110542 205 46.4942
S21P 2156905 2425532 268628 480 118.579
S75P 2156905 2261555 104651 192 45.9219
S121P 2159621 2262915 103295 192 44.5157
S115P 2165989 2292816 126828 250 65.862
S104P 2191119 2387096 195978 341 74.2499
S120P 2191119 2308917 117799 218 50.8112
S123P 2233543 2385251 151709 284 68.3263
S38P 2233543 2440576 207034 372 67.4105
S95P 2233543 2387096 153554 289 49.5405
S41P 2242435 2445918 203484 358 79.6654
S18P 2253669 2381284 127616 234 42.2847
S127P 2264880 2405095 140216 253 52.8612
S84P 2264880 2425532 160653 281 68.3503
S32P 2270670 2426669 156000 276 36.1267
S20P 2276509 2385251 108743 194 32.2157
S88P 2281815 2385251 103437 178 31.6654
S117P 2283727 2384402 100676 171 38.3117
S60P 2283727 2387096 103370 176 38.4677
S20P 2409470 2594837 185368 286 33.6277
S120P 2423780 2543930 120151 187 39.6514
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